Skip to content
OpenCapital
Get started

Icahn Enterprises IEP Pharma — Cash And Cash Equivalents At Carrying Value

Other segment segments

Holding Company
$624M-52.7%
Energy
$512M-26.3%
Automotive
$51M-27.1%
Food Packaging
$29M+383%
Investment
$16M+33.3%
Home Fashion
$5M+66.7%

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$4.9B+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by Icahn Enterprises in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Icahn Enterprises's pharma — cash and cash equivalents at carrying value.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Icahn Enterprises's pharma — cash and cash equivalents at carrying value?
Icahn Enterprises (IEP) reported pharma — cash and cash equivalents at carrying value of $27M in Q1 2026.
How has Icahn Enterprises's pharma — cash and cash equivalents at carrying value changed year-over-year?
Icahn Enterprises's pharma — cash and cash equivalents at carrying value decreased by 34.1% year-over-year, from $41M to $27M.
What is the long-term trend for Icahn Enterprises's pharma — cash and cash equivalents at carrying value?
Over 4 years (2021 to 2025), Icahn Enterprises's pharma — cash and cash equivalents at carrying value has grown at a 39.4% compound annual growth rate (CAGR), from $36M to $136M.
What does pharma — cash and cash equivalents at carrying value mean?
Represents the highly liquid assets held by the Pharma segment that can be readily converted into cash to meet short-term obligations. This metric serves as a measure of the segment's immediate financial flexibility and liquidity position. It indicates the segment's ability to fund internal projects or respond to unforeseen operational needs.